RxDoctor Payments Data

Hima Punukollu, MD

Internal Medicine · Brooklyn, NYNPI 1104989490

Payments from drug & device makers

$905in general payments, 2019–2025

Across 41 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$293
  • Exact Sciences$257
  • Novo Nordisk$122
  • Boehringer Ingelheim$105
  • AstraZeneca$56
  • E.r. Squibb & Sons, L.L.C.$19
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$905 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$158,570
Medicare patients
283
Services billed
1,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin236$252,183
OzempicSemaglutide131$191,779
EliquisApixaban117$126,787
JanuviaSitagliptin Phosphate108$116,317
MounjaroTirzepatide31$61,386
FarxigaDapagliflozin Propanediol52$46,201
TrulicityDulaglutide25$45,789
XareltoRivaroxaban34$41,047
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog60$20,195
Soliqua 100-33Insulin Glargine/Lixisenatide12$18,704
TradjentaLinagliptin21$18,227
JanumetSitagliptin Phos/Metformin Hcl15$13,248
Amlodipine-ValsartanAmlodipine Besylate/Valsartan269$12,715
Atorvastatin Calcium858$9,443
Breo ElliptaFluticasone/Vilanterol17$9,261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$105$270,409257 claims
Novo NordiskOzempic$122$191,779131 claims
Lilly USA, LLCMounjaro, Trulicity$293$107,17556 claims
AstraZenecaFarxiga$56$46,20152 claims
Johnson & JohnsonXarelto$17$41,04734 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$18$18,70412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →